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This issue of Intensive Care Medicine presents two
aspects of the difficulties that face Independent Ethics
Committees (IEC) regarding their role and responsibili-
ties, and not resolved either by the European Directive or
by its translation in national laws: a negative point of
view on the utility of European IECs through a survey
among authors of clinical trials published in some major
journals in 2007 [1], and a constructive initiative of the
Vienna university IEC, on reviewing interventional
studies at minimal risk through an expedited process [2].
Since the release of the 2001 European Union Clinical
Trials Directive (EU CTD) (2001/20/EC), an approval
from an IEC is mandatory before starting an interventional
clinical trial. Moreover, the composition of the IECs has
been widened to other categories of the civil society
among which of the users’ and patients’ representatives.
However, the EU Directive is still not entirely enforced
by all national countries such as the requirement that
explicitly requests a single IEC approval within each
national country. In Germany, a local IEC approval is
needed for every investigational centre, plus a national
IEC opinion, meaning that if you plan a multicenter trial,
involving, e.g., 20 German centres, 20 local IEC positive
approvals are required [3]. A question comes inevitably
from this observation: what is the added benefit of 20 IEC
opinions? At least, every supplementary local IEC opinion
should improve a little bit the ethical and scientific integ-
rity of the submitted clinical trial. If not and it is probably
the case, then the associated-burden appears useless.
The paper of Pehboeck et al. [1] reports the dissatis-
faction of 193 authors regarding IECs and clinical trials
registers and who have published results of clinical trials
in selected major journals in 2007. The negative percep-
tion of authors (on a scale from -10 to ?10) is consistent
across all five items in terms of support provided by IEC,
effort needed to obtain approval, and friendliness of the
approval procedure. The worst negative scores (reaching
-4) were for the two items ‘‘effort needed to obtain IEC
approval caused us to make progress in ethics or to make
scientific progress’’. However, this online survey of cor-
responding authors which was deliberately brief in order
to achieve a high return rate (80%) does not permit to give
the definite reasons of this high dissatisfaction. It can be a
very subjective perception that the IEC submission pro-
cess is just an additional bureaucratic burden. This
dissatisfaction may also reveal a deeper pitfall, i.e. the
added value of IECs and their comments on ethics and on
methodology of the submitted clinical trials are truly
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questionable. It would have been also interesting to know
whether there is a cluster of IECs associated with the
worst perception, and to look for the reasons: a skilled and
in-depth expertise of the dossier by the IEC (thus useful,
although annoying for the applicants) or a useless per-
nickety review on details. Indeed—and it is a hypocrisy
not to face this reality—applicants know quite well which
IECs provide balanced and reasonable queries. This last
point is one of the major reasons why applicants repeat-
edly deplore the heterogeneity of IECs and ask for
changes [4].
The paper of Pehboeck et al. [1] has the merit to raise
the crucial question whether IECs are competent for
giving ethical and scientific opinions. Indeed, the role of
IECs is not to refine continuously the major ethical
principles that rule the clinical research. This is devoted
to international organizations (such as Helsinki). For
example, it is not the role of IECs to decide, and to have
opposite position between IECs, whether in general a
placebo arm in clinical research is ethical or not (obvi-
ously a placebo arm is unethical when an efficient
treatment is available for a fatal or severe pathology). The
right inquiry of an IEC for a given clinical trial is to
ensure that all actions to reduce the potential risks of
being under placebo have been implemented in the pro-
tocol (e.g. strict eligibility criteria, frequent visits, add-on
therapy, early stopping rules, rescue treatment, unbal-
anced randomisation scheme…) [5].
The EU directive is considered to impose unnecessary
administrative burden and costs which are especially
problematic for investigator-initiated and academic-
sponsored clinical research.
Indeed, EU CTD has been mainly set up for pharma-
ceutical industry-sponsored clinical trials on medicinal
products and thus excludes a broad range of clinical
research (e.g. interventional trials of surgical procedures
or medical devices). Especially, the EU CTD ignores
totally the case of clinical trials at no or minimal risk
(added by the research). These latter trials include typi-
cally (1) studies with additional exams such as blood
puncture, radiography…; (2) evaluation of usual care or
of optimised management based on consensus confer-
ences or recommendations, which may not be currently
implemented in clinical practice [6]; (3) interventional
studies at minimal risk, especially those in primary care
and borderline with epidemiology, such as wearing a
mask in prevention of flu. However, this type of research
currently falls under the same biomedical research regu-
lation as for a new drug clinical trial. This inappropriate
burden on minimal risk research is shared across all
Europe. Recently, authors reported that in UK, moreover
an opinion from a Patient Information Advisory group is
also required, which ability to answer quickly may not be
its major matter. Authors plead wisely for returning
Patient Information Advisory group responsibilities to
IECs [6].
The paper by Wolzt et al. [2] presents the initiative of
the Vienna IEC, to shorten the review process of clinical
trials in which the intervention is at minimal risk. Authors
mean by minimal risk, that harm or discomfort anticipated
in the research or by standard tests should not be greater
than that encountered in daily practice or during the
performance of non-invasive routine examinations [2].
The expedited review applies also to medical research
projects involving drugs or medical devices when they are
used in accordance with their marketing authorisation.
Protocols at minimal risk are identified by the chair and
reviewed by a selected group of IEC members. The
review of this expedited board is then submitted to the full
IEC.
This comprehensive attitude of the Vienna IEC, while
probably a little outside the current European legislation
is a light of hope in a grey horizon, where the nervousness
of IECs to assume their responsibilities is equal to their
over-legalism (nothing less than, but sometimes more
than what is required by the law) and prevents any con-
sideration to help and facilitate the clinical research
notably that at minimal or no risk. This experience, fruit
of a reasoned and enlightened approach, which allows
adapting the extent of the IEC expertise to the expected
risks of the study strongly deserves to be known by
clinicians and IECs.
Role and responsibilities of IECs should be refined
IECs should consider whether they do only and respect
strictly what has been fixed by the law, knowing that the
current law is incomplete and written for industry-spon-
sored clinical trials with medicinal products. In that case,
at least they should not require from applicants and
investigators more that what is required by the law [4].
This legalist behaviour, although the most respectful of
the current regulation, underestimate a whole part of
the clinical research mostly supported by academic and
funded in many cases by governmental agencies.
The other solution is to function like an US Institu-
tional Review Board which gives opinion on all clinical
studies. This needs of course to endorse some borderline
decisions and to accept to tailor the depth of the review
process based on the expected risks/constraints of the
study. This would allow to quickly review interventional
studies with no or minimal risk, and to review even more
quickly non-interventional studies. The paper of Wolzt
et al. [2] reminds us that since 1998 in USA, Ethics
Committees are enabled to give such a fast track approval
of clinical studies with minimal risk, including studies of
drugs and medical devices. Why what is done since
10 years in USA, could not be implemented and
improved in Europe? If nothing changes, there is a risk
of having two categories of European IECs: those
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functioning as defined by the current law and those
functioning already more as IRBs (some even being
agreed by the US administration). The latter may be better
predisposed or open-minded to review all types of clinical
research and may have an improved assessment of the
benefit/risk ratio, which is the basis of the IEC approval.
Indeed, open-minded does not mean a less rigorous or less
independent process.
The EU Directive should endorse a simplified proce-
dure for minimal risk interventional trials, and should
consider that all research on human, including non-
interventional studies should be submitted to an IEC, as
currently most of authors of these studies seek an opinion
from an IRB for them to publish their results. It is
worthwhile to mention that the French parliament has just
amended the law on biomedical research in that way [7].
Obviously, the extension of a mandatory IEC approval for
non-interventional studies is possible only if all IECs do
not have an a priori against this type of research. Indeed
for some of IECs a non-interventional study is some kind
of under-research. If this prerequisite is not satisfied, the
risk is high that some IECs will reclassify these studies as
interventional with the entire associated useless burden,
e.g. as soon as the smallest additional clinician- or
patient-reported questionnaire would be part of the out-
comes, as it is the case in most studies.
Conclusion
Haven’t we been too far? i.e. too many procedures and
safeguards applied without discernment to all kinds of
research did kill the original purpose of regulation, that
was to protect patients and to ensure the fulfilment of the
basic ethical principles [4]. The two papers of this journal
issue report accurately two contrasted visages of IECs.
However, procedures, role, and expertise of IECs have to
be refined rapidly and subsequently applied by all Euro-
pean IECs. The major issue is whether Europe is capable
to adjust the administrative burden to the expected risks/
constraints added by the research. If not, some voices may
raise with legitimacy for shutting down IECs, and for
recreating new well-ordered structures with well-defined
roles.
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